Clinical trials: Melanoma
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Advanced Cancer, Melanoma
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced…
- Conditions
- Advanced Cancer, Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT02658890
- Testing
- BMS-986205, Nivolumab, Ipilimumab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 627 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Unsatisfied Needs
Holistic Needs Assessments in Patients With Melanoma
This study will assess whether a needs assessment/management intervention for patients with malignant melanoma is achievable, reasonable, realistic and of value to patients with malignant melanoma and health professionals…
- Trial name
- NCT06189261
- Testing
- Holistic needs assessment based on the use of patient-reported outcome measures
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Surrey
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Melanoma, Merkel Cell Carcinoma
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT03901573
- Testing
- NT-I7, atezolizumab
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- NeoImmuneTech
Melanoma (Skin)
Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number.
This study evaluates the effectiveness of applying Hypertonic Saline solution directly on the Melanomas in reducing their sizes and/or number.
- Trial name
- NCT05854589
- Testing
- Sodium Chloride Granules, Water
- Volunteers
- 20 people
- Sponsor
- Rafik Batroussy
Gastrointestinal Cancer, Liver Cancer
Collecting Solid Tumor Tissue to Identify New Treatments
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells…
- Conditions
- Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer, Melanoma
- Trial name
- NCT01658917
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
The purpose of this study is to evaluate the feasibility, safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion in patients with liver metastases…
- Trial name
- HAITILS (NCT04812470)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Vastra Gotaland Region
Advanced Melanoma
Nab-PCE vs PC for MM After Failure of Anti-PD-1
This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin Endostatin for advanced melanoma after failure of PD-1 therapy.
- Trial name
- NCT03917069
- Testing
- Chemotherapeutic Combinations, chemotherapy
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Peking University Cancer Hospital & Institute
Recurrent Melanoma, Stage IIIA Melanoma
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
This phase II trial is studying how well dasatinib works in treating patients with stage III melanoma that cannot be removed by surgery or stage IV melanoma.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT00436605
- Testing
- dasatinib
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma;
Role of SLURP-1 in Melanoma and Melanoma Stem Cells
Melanoma is the most aggressive skin cancer, with a propensity to metastasize, and is resistant to most of the current therapeutic regimens.
- Trial name
- NCT01281722
- Where
- Taiwan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic
Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma
This study is being done to find the best dose of an investigational drug called NBM-BMX for people with metastatic uveal melanoma, a type of eye cancer that has spread to other parts of the body.
- Conditions
- Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma
- Trial name
- NBM-BMX-UM (NCT07136181)
- Testing
- NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Novelwise Pharmaceutical Corporation
Uveal Melanoma, Metastatic
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp
The goal of this clinical trial is to learn if a low dose of dexamethasone can prevent cytokine release syndrome in participants treated with tebentafusp for advanced uveal melanoma.
- Trial name
- LODEXA (NCT07803562)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Diego
Metastatic Melanoma, Melanoma
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
- Conditions
- Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
- Trial name
- ML28604 (NCT01876641)
- Testing
- Vemurafenib + Cobimetinib, Decitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mohammed M Milhem
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Intraocular Melanoma
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00952939
- Testing
- fluorescence in situ hybridization, laboratory biomarker analysis, fine-needle aspiration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Case Comprehensive Cancer Center
Melanoma (Skin)
Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of the cancer cells.
- Trial name
- NCT00002669
- Testing
- aldesleukin, recombinant interferon alfa, cisplatin
- Where
- 24 sites in Austria, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Solid Tumor
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: Pembrolizumab AMG386
- Trial name
- NCT03239145
- Testing
- Pembrolizumab, Trebananib
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
The purpose of this study is to determine whether Ipilimumab will extend the life of chinese patients with Chemotherapy Naive Stage IV Melanoma more than Dacarbazine as well as to examine safety in this patient population.
- Trial name
- NCT02545075
- Testing
- Ipilimumab, Dacarbazine
- Where
- 8 sites in China
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb